LIVER SBRT FOR
HCC AND LIVER METASTASES
When surgery, RFA, and TACE are not options โ SBRT delivers ablative radiation to liver tumours with precision, sparing healthy liver and achieving durable local control.
analyticsAt a Glance
- check_circle80โ90% local control at 2 years in prospective series
- check_circleEffective for tumours unsuitable for RFA (>3 cm or near vessels)
- check_circle3โ6 fractions completed in 1โ2 weeks
- check_circleSuitable for Child-Pugh A and selected Child-Pugh B patients
How Liver SBRT Works
Liver SBRT uses real-time image guidance and respiratory motion management to target liver tumours with millimetre accuracy, delivering ablative doses across 3โ6 fractions while protecting the remaining liver parenchyma.
HCC (Hepatocellular Carcinoma)
For patients with cirrhosis who are not surgical candidates and have lesions not amenable to RFA or TACE, SBRT provides a bridging or definitive treatment with well-documented local control and safety in Child-Pugh A liver function.
Liver Metastases
Colorectal, breast, and neuroendocrine liver metastases respond well to SBRT. It is preferred over RFA for lesions >3 cm, centrally located tumours, or those adjacent to major hepatic vessels where thermal ablation carries high risk.
Liver SBRT: Key Outcome Data
- 80โ90%2-Year Local Control (HCC)Across prospective series and RTOG 1112 data
- 75โ85%2-Year Local Control (Liver Mets)For colorectal and other histologies
- 6โ7%Grade โฅ3 Hepatic ToxicityMaintained with mean liver dose constraints
- 3โ6Fractions RequiredTypically completed in 1โ2 weeks
Patient Eligibility: HCC vs Liver Metastases
Eligibility differs between HCC (where liver function is critical) and metastatic disease (where tumour burden and systemic disease status guide selection).
| Criteria | HCC | Liver Metastases |
|---|---|---|
| Liver function | Child-Pugh A preferred; selected CP-B7 | Normal function expected; adequate liver reserve required |
| Tumour size | Up to 6 cm in most series; larger possible | Best evidence for โค5 cm per lesion |
| Number of lesions | 1โ3 liver lesions | 1โ5 lesions (oligometastatic setting) |
| Prior treatment | Post-TACE, bridge to transplant | Post-systemic therapy; prior RFA recurrence |
| Contraindications | Child-Pugh C; prior whole-liver RT | Diffuse hepatic metastases; insufficient liver volume |
Liver SBRT vs RFA and TACE
Treatment choice depends on tumour size, location, vascular proximity, and liver reserve.
SBRT Preferred When
- Tumour >3 cmRFA has incomplete ablation rates >50% for lesions above this size
- Adjacent to major vesselsHeat-sink effect reduces RFA efficacy near hepatic veins/portal structures
- Multiple prior RFA attempts failedSBRT can achieve control in RFA-refractory lesions
- Portal vein tumour thrombus (HCC)SBRT with PVTT is an accepted indication in Asian guidelines
RFA/TACE Preferred When
- Tumour โค2 cmRFA achieves near-complete ablation with minimal toxicity
- Child-Pugh C with preserved portal flowTACE may be preferred to preserve liver function before transplant
- Multifocal bilobar HCCTACE covers multiple segments in one session
Local Control by Tumour Type
Liver SBRT delivers consistent local control across primary and metastatic hepatic tumours.
2-Year Local Control Rates
- HCC (Child-Pugh A)87%
- Colorectal Liver Metastases82%
- Breast Cancer Liver Metastases80%
- Neuroendocrine Liver Metastases85%
Related SBRT Guides
Explore how SBRT is applied across different cancer types and settings.
Frequently Asked Questions
Liver SBRT
Can liver SBRT be given to patients with cirrhosis?
Yes, in selected patients. Child-Pugh A cirrhosis is the standard eligibility criterion, with published safety data showing acceptable liver toxicity when mean liver dose and volume constraints are respected. Child-Pugh B7 patients can be considered at experienced centres with careful dose planning. Child-Pugh C cirrhosis is generally a contraindication due to limited hepatic reserve.
Is liver SBRT effective for colorectal liver metastases?
Yes. Prospective data show 2-year local control rates of 75โ85% for colorectal liver metastases treated with SBRT. It is particularly valuable for patients with oligometastatic disease after chemotherapy, or for those with RFA-unsuitable lesion locations. Combined with systemic therapy, liver SBRT can contribute to long-term disease control in oligometastatic colorectal cancer.
How is liver motion managed during SBRT?
Liver moves 1โ3 cm with each breath cycle. Centres use respiratory motion management strategies including abdominal compression, active breath hold, or real-time tumour tracking (e.g., CyberKnife, gating) to ensure the beam tracks the tumour. Daily CBCT or MRI guidance confirms tumour position before each fraction.
Can liver SBRT be used as a bridge to transplantation in HCC?
Yes. SBRT is increasingly used as a bridging therapy to liver transplantation in HCC patients awaiting organ availability. It can achieve durable local control for 6โ18 months, preventing tumour progression beyond Milan criteria during the waiting period. Several transplant centres now accept SBRT as equivalent to locoregional therapy for downstaging or bridging.
Where can I access liver SBRT in India or China?
Liver SBRT is available at major hepatobiliary oncology centres in India (Tata Memorial Hospital, AIIMS New Delhi, HCG network) and China (Zhongshan Hospital Shanghai, PUMCH Beijing, Sun Yat-sen University Cancer Centre). CancerFax can assess your eligibility and coordinate consultations at the most appropriate centre based on your liver function and tumour characteristics.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is Liver SBRT an Option for Your Case?
Upload your liver imaging, AFP levels, and Child-Pugh score. Our team will assess SBRT eligibility and identify specialist centres in India or China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.